Related references
Note: Only part of the references are listed.Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial
Yoshiki Hirooka et al.
ONCOTARGET (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study
Nobuaki Suzuki et al.
CANCER SCIENCE (2017)
Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer
Yoshitaro Shindo et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy
Hiroto Matsui et al.
PANCREAS (2017)
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
Gary Middleton et al.
BRITISH JOURNAL OF CANCER (2016)
Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion
Yosuke Kano et al.
CANCER SCIENCE (2016)
Antitumor activity and immune reponse in CD40 immunotherapy with gemcitabine and nab-paclitaxel in an orthotopic pancreatic cancer mouse model.
Despina Siolas et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Timothy M. Nywening et al.
LANCET ONCOLOGY (2016)
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Hong Jiang et al.
NATURE MEDICINE (2016)
Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study
Hiroki Yamaue et al.
CANCER SCIENCE (2015)
Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer
Shuhei Mayanagi et al.
CANCER SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
VEGF expression in pancreatic cancer and other malignancies: a review of the literature
M. I. Costache et al.
ROMANIAN JOURNAL OF INTERNAL MEDICINE (2015)
Immunological off-target effects of standard treatments in gastrointestinal cancers
A. G. Duffy et al.
ANNALS OF ONCOLOGY (2014)
Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)-Specific MHC Class I/II-Restricted Epitopes for Pancreatic Cancer
Shigeo Koido et al.
CLINICAL CANCER RESEARCH (2014)
Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer
Yoshitaro Shindo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton et al.
LANCET ONCOLOGY (2014)
Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
Eric R. Lutz et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Karolina Palucka et al.
IMMUNITY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Active immunotherapy for mouse breast cancer with irradiated whole-cell vaccine expressing VEGFR2
Heng-Xiu Yan et al.
ONCOLOGY REPORTS (2013)
VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2
Apostolos C. Ziogas et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
MUC1 regulates PDGFA expression during pancreatic cancer progression
M. Sahraei et al.
ONCOGENE (2012)
Clinical and Immunologic Evaluation of Dendritic Cell-Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma
Yukino Kimura et al.
PANCREAS (2012)
nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
Kristopher K. Frese et al.
CANCER DISCOVERY (2012)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer
Motoki Miyazawa et al.
CANCER SCIENCE (2010)
VEGFR2 is selectively expressed by FOXP3(high) CD4(+) Treg
Hiroyuki Suzuki et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer
Takashi Hirose et al.
ONCOLOGY REPORTS (2010)
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment
Youjin Lee et al.
BLOOD (2009)
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
David Cunningham et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Increased survivin expression confers chemoresistance to tumor-associated endothelial cells
Jenilyn J. Virrey et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer
Min Li et al.
MOLECULAR CANCER THERAPEUTICS (2008)
A late phase II study of S-1 for metastatic pancreatic cancer
Takuji Okusaka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Dynamic intracellular survivin in oral squamous cell carcinoma:: underlying molecular mechanism and potential as an early prognostic marker
K. Engels et al.
JOURNAL OF PATHOLOGY (2007)
A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer
Hideki Ueno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin
Marion Wobser et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor
AA Lugade et al.
JOURNAL OF IMMUNOLOGY (2005)
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
AM Ercolini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer
RK Ramanathan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
A Rump et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients
M Ducreux et al.
ANNALS OF ONCOLOGY (2004)
Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts
RG Azrak et al.
CLINICAL CANCER RESEARCH (2004)
Mesothelin-specific CD8+ T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients
AM Thomas et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma
Y Oji et al.
CANCER SCIENCE (2004)
Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator - Involvement of Toll-like receptor 4
SU Ahmed et al.
JOURNAL OF IMMUNOTHERAPY (2004)
The tuberin-hamartin complex negatively regulates β-catenin signaling activity
BC Mak et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer
H Shinchi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies
OA Elisseeva et al.
BLOOD (2002)
The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas
J Lüttges et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2002)
The human kinesin-like protein RB6K is under tight cell cycle control and is essential for cytokinesis
RD Fontijn et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
The Rab6-binding kinesin, Rab6-KIFL, is required for cytokinesis
E Hill et al.
EMBO JOURNAL (2000)
Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model
Y Yamashita et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
J Schüller et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
Share Paper
